EuroBiotech: More Articles of Note


> Genmab outlined plans to increase its spending by as much as 45% in 2020. The anticipated surge in operating expenses reflects Genmab’s plans for development of its CD3xCD20 and PD-L1x4-1BB bispecifics. Annual report

> Montis Biosciences raised €8.4 million ($9.1 million) to advance immuno-oncology treatments for solid tumors. Pfizer Ventures was among the organizations to invest in the round. Statement 

> Mereo BioPharma received a $3 million equity investment. The U.S. investor bought the stock at a 20% discount to Mereo’s closing price the day before the deal was disclosed. Release 

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

> DuPont Nutrition & Biosciences entered into a collaboration with MRM Health. The collaborators will combine DuPont’s strains with MRM’s technology to create microbiome-based therapeutics. Statement 

> A Parkinson’s disease collaboration between Servier and Oncodesign passed its first milestone. The event triggered a €1 million milestone payment from Servier. Release 

> The U.K. government made Pfizer’s old Sandwich campus one of six Life Science Opportunity Zones. Government officials will work with the zones to attract investment. Statement 

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.